Real-Time Margin Measurement
for Precision Cancer Surgery
Navigation Sciences is developing the NaviSci™ system to address the growing need to locate and remove lung and other soft tissue cancers.
Real-time GPS
Navigation
Precise Margin
Control
Minimally
Invasive
NaviSci’s first application is in early-stage lung cancer, where there are more than 76,000 new cases each year in the U.S.; the number is growing annually due to increasing adoption of CT x-ray screening.
Overall, there are approximately 450,000 soft tissue cancer diagnoses annually in the U.S. where NaviSci has potential application.
Recent News
NaviSci Q3/ 2021 Progress updates in the development of our NaviSci™ Intelligent Surgical System for the localization and removal of early-stage lung tumors
NaviSci Q3/ 2021 Progress updates in the development of our NaviSci™ Intelligent Surgical System for the localization and removal of early-stage lung tumors Read more
Navigation Sciences™ Awarded $400,000 NCI SBIR/STTR Program Grant to Support Development of NaviSci™ Intelligent Surgical System Use in Removal of Early-Stage Lung Tumors
Navigation Sciences™ Awarded $400,000 NCI SBIR/STTR Program Grant to Support Development of NaviSci™ Intelligent Surgical System Use in Removal of Early-Stage Lung Tumors Read more
Joining Navigation Sciences board of directors are Carl Berke, Ph.D. Partner at the MassGeneral Brigham Venture, and Steve Gullans, Ph.D. Principal at Gullans Advisory
Joining Navigation Sciences board of directors are Carl Berke, Ph.D. Partner at the MassGeneral Brigham Venture, and Steve Gullans, Ph.D. Principal at Gullans Advisory Read more
Navigation Sciences awarded U.S. patent covering NaviSci™ Intelligent Surgery system and other recent company progress
Navigation Sciences awarded U.S. patent covering NaviSci™ Intelligent Surgery system and other recent company progress Read more
Navigating Through Early-Stage Lung Cancer, published in Medical Device and Diagnostic Industry Online
Navigating Through Early-Stage Lung Cancer, published in Medical Device and Diagnostic Industry Online Read more
Navigation Sciences™ Begins First-in-Human Clinical Feasibility Trial of its Pioneering, NaviSci™ System for Tissue-Conserving Removal of Early-Stage Lung Tumors
Navigation Sciences™ Begins First-in-Human Clinical Feasibility Trial of its Pioneering, NaviSci™ System for Tissue-Conserving Removal of Early-Stage Lung Tumors Read more
NaviSci is based on technology developed by the company’s co-founders, leaders in thoracic surgery and advanced surgical navigation technology, Raphael Bueno, M.D., Chief, Thoracic Surgery, and Jayender Jagadeesan, Ph.D., Associate Professor of Radiology both at Brigham & Women’s Hospital and Harvard Medical School. View our leadership team
